Top Ten most popular articles on Pharmafile.com of 2018!

Image Credit: patricia m https://www.flickr.com/photos/taffeta/38707779504/

Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical industry continued to innovate. The top story of the year covered the fact that Amgen’s biosimilar prove non-inferior to Johnson & Johnson’s Remicade in rheumatoid arthritis. Meanwhile the British parliament’s choice to remain within the EMA regulatory network took second place, followed closely behind by the launch of another high profile biosimilar.

On the business side GSK was named the UK’s third best workplace, while Novartis CEO Vasant Narasimhan said he sought to un-boss the company’s culture in a bid to appeal to millennials.

Check out this year’s top 10 stories at Pharmafile.com!

10. Switching to Gilead's Biktarvy proves non-inferior in HIV patients

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from a range of regimens.

9. US Senate pass bipartisan bill to tackle opioid crisis

The US Senate have passed a bipartisan bill aimed at combatting the opioid crisis through new research, treatment and help for families suffering from the effects of the opioid addiction epidemic that has swept through the United States in recent years.

8. Novartis CEO calls for cultural shift to cater for millennial generation

The CEO of Swiss multinational Novartis has said that he wants to ‘un-boss’ the multi-billion pound company while relaxing the firm’s rules by allowing employees to wear jeans to work.

7. FDA finds major manufacturing issues at key Aurobindo facility

Indian pharmaceutical firm Aurobindo has been rocked by an USFDA review which identified nine major issues with its Unit 4 facility in Hyderabad, India, which focuses on the manufacture of generic sterile injectables, ophthalmics and low volume parenterals.

6. Six reasons why UK pharma has more to gain, than fear, from Brexit

There are good reasons to think exiting the EU represents a major opportunity for this dynamic and world-leading industry, argues Tom Cowap of Catalyst Corporate Finance.

5. GSK named third best UK workplace

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs website Indeed’s list of top rated workplaces in the private sector in Britain.

4. Ontruzant launches to become first Herceptin biosimilar available in the UK

Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in the UK, becoming the first biologic copycat version of Roche’s blockbuster to be available in the region.

3. Novartis Pharma Ex-CEO takes three roles in two days

Former CEO of Novartis Pharmaceuticals, David Epstein, has had a busy start to the year, accepting not one but three new positions in two days.

2. MPs vote to stay in EMA after Brexit

British MPs have voted for the UK's continued participation in the regulatory network operated by the European Medicines Agency (EMA) after Brexit.

1. Amgen biosimilar proves non-inferior to J&J's Remicade in rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade, confirming that it demonstrated non-inferiority compared to its reference product in the treatment of moderate-to-severe rheumatoid arthritis.